Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.
Standard
Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way. / Carmeliet, Peter; Frederik, De Smet; Loges, Sonja; Mazzone, Massimiliano.
in: NAT REV CLIN ONCOL, Jahrgang 6, Nr. 6, 6, 2009, S. 315-326.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.
AU - Carmeliet, Peter
AU - Frederik, De Smet
AU - Loges, Sonja
AU - Mazzone, Massimiliano
PY - 2009
Y1 - 2009
N2 - From the original concepts that tumors require a vascular supply to grow and that blocking angiogenesis could suppress tumor growth, the oncology field has witnessed clinical successes of VEGF-targeted antiangiogenic medicine. The field is now facing the challenge of overcoming resistance to VEGF-targeted therapy, and therefore additional angiogenesis inhibitors are being developed. Studies on how endothelial 'tip, stalk and phalanx cells' form sprouts have identified promising candidate targets with complementary mechanisms to VEGF. This Review provides a conceptual framework in which molecular discoveries and principles are discussed in light of clinical opportunities to develop new antiangiogenic agents.
AB - From the original concepts that tumors require a vascular supply to grow and that blocking angiogenesis could suppress tumor growth, the oncology field has witnessed clinical successes of VEGF-targeted antiangiogenic medicine. The field is now facing the challenge of overcoming resistance to VEGF-targeted therapy, and therefore additional angiogenesis inhibitors are being developed. Studies on how endothelial 'tip, stalk and phalanx cells' form sprouts have identified promising candidate targets with complementary mechanisms to VEGF. This Review provides a conceptual framework in which molecular discoveries and principles are discussed in light of clinical opportunities to develop new antiangiogenic agents.
M3 - SCORING: Zeitschriftenaufsatz
VL - 6
SP - 315
EP - 326
JO - NAT REV CLIN ONCOL
JF - NAT REV CLIN ONCOL
SN - 1759-4774
IS - 6
M1 - 6
ER -
